IL2 and renal cell carcinoma: A high-dose IL2 regimen administered every 8 hours in a hospital setting using an IL2 variant known as ‘aldesleukin’ was approved in the 1990s by the United States Food and Drug Administration for the treatment of metastatic melanoma and renal cell carcinoma, providing up to 25% durable responses [10, 11].